Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-δ-mediated transcriptional mechanism.

Prospective evidence provided by the JUPITER trial (justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin) demonstrated that rosuvastatin-treated patients with normal LDL-C levels, but elevated baseline CRP levels, showed highly significant (− 44%) reduction in adverse cardiovascular events [ 14 , 19 ], suggesting additional benefits of CRP reduction, and further demonstrating an inflammatory component in CVD risk [ 16 ].

also in 132,142 other papers